Chimin(603222.SH)

Chimin: Plans to repurchase shares worth 100 million to 200 million yuan, with a total repurchase of 12.089 million yuan already completed

Chimin announced that the company will repurchase shares through centralized bidding trading on March 28, 2025, with a repurchase amount of 100 million to 200 million yuan, and the period is 12 months from the date of the board of directors' approval, for the employee stock ownership plan or equity incentive. As of October 31, 2025, the company has repurchased a total of 2.0055 million shares, accounting for 0.38% of the total share capital, with a total payment of 12.089 million yuan, and the repurchase price range is 5.87-6.13 yuan/share. No repurchase was implemented in October 2025

Chimin disclosed the progress of its share repurchase, having repurchased a total of 2.0055 million shares

Chimin Health Management Co., Ltd. plans to repurchase 2.0055 million shares through a share repurchase plan on March 28, 2025, accounting for 0.3819% of the total share capital. The repurchase price will not exceed 10 yuan per share, with a total fund amount of 100 million to 200 million, and the repurchase period is 12 months. As of September 30, 2025, 12.089 million yuan has been paid, with purchase prices ranging from 5.87 yuan to 6.13 yuan. The company reminds investors to pay attention to risks

Chimin: Currently, the stock price trend is significantly diverging from the operating performance trend

Chimin issued a risk warning announcement, stating that its stock price trend is significantly deviating from its operating performance. The company's stock closed at the daily limit today, with a turnover rate of 16.96%, and has accumulated a rise of 33.78% from September 8 to 11. However, the increase over the past 30 trading days deviates from the Shanghai Composite Index by 94.72%, and the company's net profit for the fiscal year 2024 is projected to be -59.7117 million yuan, with a net profit of -52.6959 million yuan for the first half of 2025, indicating performance losses, unchanged main business, and a risk of rapid decline

The concept of innovative drugs has rebounded, with Chimin gaining 6 limit-ups in 12 days, Staidson BioPharm rising over 7%, Hotgen increasing over 5%, and stocks like Medicilon, Cosunter, and BrightGene also seeing gains

Chimin's shareholder Shuangge Group plans to reduce its holdings by no more than 3%

According to the Zhitong Finance APP, Chimin announced that its shareholder Shuangge Group plans to reduce its holdings of the company's shares by a total of no more than 15.7527 million shares through centralized bidding and block trading, which is no more than 3% of the company's total share capital